Outcomes of patients treated through the Canadian Fabry disease initiative (Q43743815)

26 November 2017

Outcomes of patients treated through the Canadian Fabry disease initiative (English)

1 reference

26 November 2017

1 reference

S M Sirrs

1

1 reference

26 November 2017

D G Bichet

2

1 reference

26 November 2017

R Casey

3

1 reference

26 November 2017

J T R Clarke

4

1 reference

26 November 2017

K Lemoine

5

1 reference

26 November 2017

S Doucette

6

1 reference

26 November 2017

M L West

7

1 reference

26 November 2017

CFDI investigators

8

1 reference

26 November 2017

2 February 2014

1 reference

Molecular Genetics and Metabolism

26 November 2017

1 reference

26 November 2017

111

1 reference

26 November 2017

4

1 reference

26 November 2017

499-506

1 reference

Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Antiproteinuric Therapy and Fabry Nephropathy: Sustained Reduction of Proteinuria in Patients Receiving Enzyme Replacement Therapy with Agalsidase-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Vasculopathy in patients with Fabry disease: current controversies and research directions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Increased arterial stiffness is associated with high cardiovascular mortality in male Fabry patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Progression of cardiovascular damage: the role of renin-angiotensin system blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.01.014

10.1016/J.YMGME.2014.01.014

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference